Buy Rating Reiterated on ACADIA as EU Rett Prospects Strengthen; $37 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Ritu Baral reiterated a Buy rating on ACADIA Pharmaceuticals with an unchanged $37 price target. The decision is driven by strengthened prospects for EU approval of Daybu for Rett syndrome, following a positive CHMP opinion that significantly reduces regulatory risk. Baral highlights ACADIA's preparedness for a late-2026 launch and projects peak European sales of approximately $327M by 2033, supporting the bullish outlook.
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $37.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Ritu Baral has given his Buy rating due to a combination of factors tied to the advancing regulatory and commercial prospects for Daybu in Rett syndrome. The positive CHMP opinion, especially after re-examination, substantially lowers the regulatory risk for European and de facto U.K. approval, making eventual EC authorization in the coming months highly probable and strategically important for ACADIA’s growth.
Ritu also notes that ACADIA is already investing in an experienced rare-disease commercial infrastructure in Europe, positioning the company to capitalize on approval with an anticipated launch in late 2026. With an assumed initial EU net price meaningfully discounted to the U.S. level and modeled peak European sales of roughly $327M by 2033, she sees a compelling long-term revenue opportunity, supporting the unchanged $37 price target and Buy recommendation.
Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Insmed, and Palvella Therapeutics. According to TipRanks, Baral has an average return of 42.8% and a 53.33% success rate on recommended stocks.